Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8847718 | 0.78 | — | — | |
| SCHEMBL18112355 | 0.78 | MMP8 (0.36) | MMP8CYP2C19ALDH1A1TDP1 | |
| SCHEMBL301722 | 0.76 | ACACB (0.40) | MMP8CYP2C19ALDH1A1TDP1 | |
| SCHEMBL6138611 | 0.76 | ALDH1A1 (0.39) | MMP8CYP2C19ALDH1A1TDP1 | |
| SCHEMBL4602984 | 0.75 | GRM2 (0.35) | MMP8CYP2C19 | |
| SCHEMBL1262963 | 0.75 | GRM2 (0.35) | MMP8CYP2C19 | |
| SCHEMBL8847922 | 0.75 | CA1 (0.36) | — | |
| Hydrogen Peroxide SCHEMBL5147765 | 0.74 | ALDH1A1 (0.38) | MMP8CYP2C19ALDH1A1TDP1 | |
| SCHEMBL10601733 | 0.74 | CYP2C19 (0.37) | MMP8CYP2C19ALDH1A1TDP1 | |
| SCHEMBL13954104 | 0.74 | CYP1A2 (0.37) | MMP8CYP2C19ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | EMORY UNIVERSITY | 2002-09-12 | — | — | US | disclosed |
| WO-2002047679-A2 | NONPEPTIDE AGONISTS AND ANTAGONISTS OF VASOPRESSIN RECEPTORS | EMORY UNIVERSITY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | AVPR1A, AVPR2, AVPR1B | MMP8 1589/4885CYP2C19 2256/4885ALDH1A1 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.